- Colgate-Palmolive Company recently reported its second quarter 2025 financial results, posting increased sales of US$5.11 billion and net income of US$743 million, along with completing a share repurchase program worth US$257.16 million.
- An interesting insight is that the company revised its full-year guidance downward for organic sales growth, mainly reflecting its planned exit from private label pet sales and ongoing foreign exchange pressures.
- We'll now explore how the company's revised sales growth guidance could influence the broader Colgate-Palmolive investment narrative.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Colgate-Palmolive Investment Narrative Recap
To be a Colgate-Palmolive shareholder, one needs to believe in the company’s ability to drive steady long-term growth through brand strength, global reach, and ongoing innovation, despite near-term obstacles like macroeconomic headwinds and shifting consumer behavior. The latest downward revision in organic sales growth reflects challenges related to foreign exchange and the exit from private label pet sales, but does not materially shift the company’s key short-term catalyst: capturing value from premium oral care expansion. The most important risk for the business remains the potential impact of sustained consumer caution in key markets, although this news does not fundamentally alter that risk.
The announcement of a completed share repurchase program, buying back approximately US$257.16 million in shares, stands out in light of ongoing catalysts. While the buyback underscores management’s commitment to delivering shareholder value, the broader investment narrative continues to hinge on execution in core categories and navigating cost pressures, more so than near-term financial maneuvers. The tension to watch lies in whether margin improvement efforts can keep pace with...
Read the full narrative on Colgate-Palmolive (it's free!)
Colgate-Palmolive's outlook anticipates $22.4 billion in revenue and $3.5 billion in earnings by 2028. This relies on a 3.9% annual revenue growth rate and a $0.6 billion earnings increase from the current $2.9 billion.
Uncover how Colgate-Palmolive's forecasts yield a $95.06 fair value, a 12% upside to its current price.
Exploring Other Perspectives
Six independent fair value estimates from the Simply Wall St Community range from US$60.84 to US$129.42, capturing a wide spread of expectations. While many see upside, the persistence of elevated raw material costs challenges consistent profitability and could shape how these valuations play out over time.
Explore 6 other fair value estimates on Colgate-Palmolive - why the stock might be worth 28% less than the current price!
Build Your Own Colgate-Palmolive Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Colgate-Palmolive research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.
No Opportunity In Colgate-Palmolive?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
- Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com